Andrea Burón1, Jaume Grau2, Montserrat Andreu3, Josep M Augé4, Rafael Guayta-Escolies5, Mercè Barau6, Francesc Macià7, Antoni Castells8. 1. Servicio de Epidemiología y Evaluación, Hospital del Mar, Barcelona, España; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Red de investigación en servicios de salud en enfermedades crónicas (REDISSEC), Barcelona, España. Electronic address: aburon@parcdesalutmar.cat. 2. Servicio de Medicina Preventiva y Epidemiologia, Hospital Clínic, Universitat de Barcelona, Barcelona, España. 3. IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Servicio de Digestología, Hospital del Mar, Barcelona, España. 4. Servicio de Bioquímica y Genética Molecular, Centro de Diagnóstico Biomédico (CDB), Hospital Clínic, Barcelona, España. 5. Direcció de Projectes i Recerca, Consell de Col·legis Farmacèutics de Catalunya, Barcelona, España. 6. Col·legi Oficial de Farmacèutics de Barcelona, Barcelona, España. 7. Servicio de Epidemiología y Evaluación, Hospital del Mar, Barcelona, España; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Red de investigación en servicios de salud en enfermedades crónicas (REDISSEC), Barcelona, España. 8. Servicio de Gastroenterología, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones Biomédicas en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, España.
Abstract
BACKGROUND AND OBJECTIVE: The Colorectal Cancer Screening Program of Barcelona was implemented in December 2009 and involves pharmacies for the distribution and collection of screening tests. The aim of this article is to describe the main indicators of the first round of the Program (2010-2011), based on the ones suggested by the European Union. MATERIAL AND METHODS: The target population of the Colorectal Cancer Screening Program of Barcelona includes men and women aged 50-69 years who live in the catchment areas of Hospital Clínic and Hospital del Mar. Screening consists of biennial immunochemical fecal occult blood testing, with colonoscopy as confirmatory procedure. RESULTS: Target population comprised 197,795 persons. Participation rate was 43.6%, was higher among women and among those aged 60 and older. 2.1% of the eligible population stated to have been already screened for colorectal cancer. Overall positivity rate was 6.2%, higher among men and with a broad variability among health care areas. The detection rates of low- and high-risk adenoma, and of invasive cancer were 9.1 ‰, 21.7 ‰ and 3.1 ‰, respectively. 48.2% of tumors were stage i. CONCLUSIONS: These results are considered satisfactory and consistent with those obtained in other programs and with European standards. Nevertheless, some areas for improvement have been identified. The high participation rate can be attributed, at least in part, to the type of test and to the involvement of community pharmacies.
BACKGROUND AND OBJECTIVE: The Colorectal Cancer Screening Program of Barcelona was implemented in December 2009 and involves pharmacies for the distribution and collection of screening tests. The aim of this article is to describe the main indicators of the first round of the Program (2010-2011), based on the ones suggested by the European Union. MATERIAL AND METHODS: The target population of the Colorectal Cancer Screening Program of Barcelona includes men and women aged 50-69 years who live in the catchment areas of Hospital Clínic and Hospital del Mar. Screening consists of biennial immunochemical fecal occult blood testing, with colonoscopy as confirmatory procedure. RESULTS: Target population comprised 197,795 persons. Participation rate was 43.6%, was higher among women and among those aged 60 and older. 2.1% of the eligible population stated to have been already screened for colorectal cancer. Overall positivity rate was 6.2%, higher among men and with a broad variability among health care areas. The detection rates of low- and high-risk adenoma, and of invasive cancer were 9.1 ‰, 21.7 ‰ and 3.1 ‰, respectively. 48.2% of tumors were stage i. CONCLUSIONS: These results are considered satisfactory and consistent with those obtained in other programs and with European standards. Nevertheless, some areas for improvement have been identified. The high participation rate can be attributed, at least in part, to the type of test and to the involvement of community pharmacies.
Keywords:
Average-risk population; Cancer early detection; Cancer screening; Colorectal cancer; Community pharmacy services; Cribado; Cáncer colorrectal; Diagnóstico precoz; Farmacia comunitaria; Población de riesgo intermedio
Authors: Andrea Buron; Josep M Auge; Maria Sala; Marta Román; Antoni Castells; Francesc Macià; Mercè Comas; Carolina Guiriguet; Xavier Bessa; Xavier Castells Journal: PLoS One Date: 2017-06-16 Impact factor: 3.240
Authors: Marco A Alvarez-Gonzalez; Miguel A Pantaleon; Juana A Flores-Le Roux; Diana Zaffalon; Jaume Amorós; Xavier Bessa; Agustin Seoane; Juan Pedro-Botet Journal: Dis Colon Rectum Date: 2019-04 Impact factor: 4.585
Authors: Ana Isabel Cobo-Cuenca; José Alberto Laredo-Aguilera; María-Aurora Rodríguez-Borrego; Esmeralda Santacruz-Salas; Juan Manuel Carmona-Torres Journal: Int J Environ Res Public Health Date: 2019-06-14 Impact factor: 3.390